Pentavalent vaccine
| Vaccine description | |
|---|---|
| Target disease | DTP-HepB-Hib (diphtheria, tetanus, whooping cough, hepatitis B, haemophilus influenza type B) |
| Type | Conjugate vaccine |
| Clinical data | |
| Trade names | Quinvaxem, Pentavac PFS, Easyfive TT |
| Routes of administration |
Intramuscular |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
A pentavalent vaccine is a combined vaccine with five individual vaccines conjugated into one, intended to actively protect people from 5 potentially deadly diseases. The main example is a vaccine that protects against Haemophilus Influenza type B (a bacterium that causes meningitis, pneumonia and otitis), whooping cough, tetanus, hepatitis B and diphtheria.
During studies and tests, the conjugated liquid DTPw-HepB-Hib vaccine was found to have positive safety when administered as a booster to young children who have been given a vaccination course with another pentavalent booster that requires a change in constitution and was also found to be adequately immunogenic.
A typical wholesale cost of a DTPw-HepB-Hib pentavalent vaccine was about 15.40 USD in 2014.
Common versions of pentavalent vaccines include ComBE Five, Pentavac PFS, Easyfive, Pentaxim (DTaP), shan-5, and Quinvaxem (DTwP).
Pentavac PFS is a pentavalent vaccine manufactured in India by Pune-based pharmaceutical company Serum Institute of India and was the lowest cost pentavalent vaccine in India.
Produced by Panacea Biotec, Easyfive was removed from the WHO's list of pre-approved and prequalified vaccines in mid-2011. Thereafter, in September 2013, WHO re-approved Easyfive after a positive result in the re-evaluation of the vaccine.
...
Wikipedia